Can-Fite BioPharma Ltd. (CANF)

1.37
0.00 (0.00)
AMEX : Health Technology
Prev Close 1.37
Open 1.39
Day Low/High 1.34 / 1.40
52 Wk Low/High 1.24 / 2.75
Volume 61.33K
Avg Volume 144.60K
Exchange AMEX
Shares Outstanding 19.98M
Market Cap 29.50M
EPS -0.30
P/E Ratio 9.20
Div & Yield N.A. (N.A)

Latest News

Can-Fite To Present At The MicroCap Conference

Can-Fite Reports 2017 Financial Results & Provides Clinical Update
Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced...

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has...

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an...

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it...

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, announced today that...

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its...

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite BioPharma Ltd. (NYSEAM:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its...

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today reported financial...

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that...

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it will...

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced it has successfully...

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKD, CCE, CFBK, FIT Downgrades: FWRD, SIG, VIA Initiations: CANF Read on to get TheStreet Quant Ratings' detailed report:

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) shares are down over 10% after pricing its secondary registered direct offering of 1.1 million shares.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for under $10 a share look ready to break out and trade higher from current levels.

Load More
Quant Rating on 3:59 PM EDT 4/24/2018

E+

(Sell)

From Our Partners

Adenosine A3 Receptor Agonist-Namodenoson And NASH: Can-Fite Biopharma Is Fighting The Good Fight
SeekingAlpha

Can-Fite Biopharma net loss improves in FY 2017
SeekingAlpha

Can-Fite Biopharma reports FY results
SeekingAlpha

Can-Fite BioPharma downgraded to Hold from Buy at Maxim
The Fly

Can-Fite BioPharma downgraded to Hold from Buy at Maxim
The Fly

Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC
SeekingAlpha

Midday Gainers / Losers (3/9/2018)
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/9/2018)
SeekingAlpha

Key events next week - healthcare
SeekingAlpha

Premarket Losers as of 9:05 am (3/9/2018)
SeekingAlpha

Can-Fite secures $5M private capital raise; shares down 16% premarket
SeekingAlpha

Key events next week - healthcare
SeekingAlpha

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/1/2018)
SeekingAlpha

Can-Fite Biopharma Downside Risk: Paid Promos, Rehashed News, And $50M Shelf
SeekingAlpha
TheStreet Quant Rating: E+ (Sell)

Get the (CANF)
Report Here

Watchlist

Trending
Self-Inflicted Wounds: Cramer's 'Mad Money' Recap (Tuesday 4/24/18)
Three Big Factors That Rocked the Stock Market Tuesday
3 Must Know Market Insights From TheStreet's Jim Cramer Before Wednesday's Open
Why a Global Stock Market Crash Is Coming
What the Charts Say About the Big Picture: Cramer's 'Off The Charts'